HUTCHMED (China) Ltd HCM
HUTCHMED (China) Ltd (Nasdaq: HCM) is an oncology drug developer. Its lead program, Savolitinib (ORPATHYS) + osimertinib (TAGRISSO), is in Phase 3 for EGFR-mutated NSCLC with MET overexpression/amplification after EGFR-TKI progression.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Fruquintinib (Fruzaqla / Elunate) | Metastatic colorectal cancer | small molecule | Approved |
| Surufatinib (Sulanda) | Neuroendocrine tumors (China) | small molecule | Approved |
| Savolitinib + osimertinib (SAFFRON; US NDA) | EGFRm NSCLC with MET overexpression/amplification | small molecule | Phase 3 |
| HMPL-A830 (KRAS-EGFR ATTC) | Advanced/metastatic solid tumors (CRC, PDAC, NSCLC) | antibody | Phase 1 |
| HMPL-A251 (ATTC) | Solid tumors | antibody | Phase 1 |
Recent results and decisions
- Oct 21, 2026n/a HUTCHMED closes exclusive license agreement with GSK for HMPL-A830 (KRAS-EGFR antibody conjugate) outside China, receiving $110 million upfront and potential $1.185 billion in milestones.
Following the closing of the exclusive license agreement, HUTCHMED Limited expects to receive US$110 million upfront payment shortly, and may receive additional development, regulatory and commercial milestone payments of up to a total of US$1.185 billion.
Filing - Sep 29, 2026submitted AstraZeneca submitted US NDA to FDA for ORPATHYS + TAGRISSO based on SAFFRON; no PDUFA date given.
AstraZeneca has submitted a New Drug Application (“NDA”) to the US Food and Drug Administration (“FDA”) for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib)
Filing - Sep 1, 2026started HMPL-A830 Phase 1a global clinical trial initiated in China and US in September 2026 for patients with advanced solid tumors.
The Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors in China and the US was initiated in September 2026.
Filing
23 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.